Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Actifuse Flow
- Development stage
- Unknown
- Lead developer
- Baxter
- Administration
- Topical
01
Overview
Actifuse Flow is a synthetic bone graft substitute developed by Baxter International Inc. and cleared by the FDA in 2018 as a medical device. It is classified as a bone void filler for orthopedic applications, specifically designed for filling gaps in the skeletal system including the extremities, pelvis, and spine. The product utilizes a proprietary silicate-substituted technology that enhances silicon levels to accelerate bone formation. Delivered in a prepackaged, ready-to-use syringe, it maintains a flowable consistency during surgery and is eventually resorbed and replaced by the patient's natural bone during the healing process.
- Brand names
- Actifuse Flow
Beyond the preview
Go deeper on Actifuse Flow.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Actifuse Flow.